Company profile: Spotlight Innovation
1.1 - Company Overview
Company description
- Provider of support for commercializing healthcare technologies developed in America's powerhouse academic laboratories, including acquisition and development of medical sector intellectual property; patented Crotoxin administration for IV treatment of pain and neurologic or neuromuscular disorders; FDA-registered EPISORB using cardiotoxin as a cell-penetrating peptide; and cancer and pain therapeutics via Celtic Biotech Iowa.
Products and services
- Healthcare IP Acquisition: Industry-grade service that identifies and acquires promising medical-sector intellectual property for development and commercialization, targeting healthcare technologies originating in America's powerhouse academic laboratories
- EPISORB: FDA-registered cardiotoxin-based cell-penetrating peptide product architected for compounding pharmacy distribution, enabling cell penetration to facilitate therapeutic administration
- Crotoxin Administration: Patented method using Crotoxin compositions intravenously to treat pain and neurologic or neuromuscular disorders, specifying IV administration for targeted therapeutic effect
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spotlight Innovation
Athersys
HQ: United States
Website
- Description: Provider of an adult-derived, off-the-shelf stem cell therapy platform, MultiStem, for neurological, inflammatory and immune, cardiovascular, and other critical care indications. Conducts clinical trials and programs including MASTERS-2 and TREASURE for stroke, and AMI, PVD, and congestive heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Athersys company profile →
Biotest
HQ: Germany
Website
- Description: Provider of plasma proteins and biotherapeutic drugs for haematology, clinical immunology and intensive care medicine, developing, manufacturing and marketing immunoglobulins and clotting factors, with a value chain extending from pre-clinical and clinical development to worldwide marketing and distribution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotest company profile →
Oxford Biomedica
HQ: United Kingdom
Website
- Description: Provider of gene and cell therapy solutions, offering lentiviral LentiVector and AAV platforms for development and manufacturing of gene therapies, plus CDMO services for viral vectors including tech transferred-in execution of client-defined methods, process development, GMP manufacturing, and regulatory support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Biomedica company profile →
Paion
HQ: Germany
Website
- Description: Provider of biopharmaceutical products; develops and commercializes drug candidates for diseases or interventions with substantial unmet medical need. Lead compound: remimazolam, an intravenous, ultra-short-acting, controllable benzodiazepine. Portfolio: Byfavo (procedural sedation, general anesthesia); Angiotensin II/GIAPREZA (refractory hypotension in septic or distributive shock); Eravacycline/XERAVA (complicated intra-abdominal infections in adults).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paion company profile →
Animol Discovery
HQ: United States
Website
- Description: Provider of a drug discovery platform combining DNA-encoded chemical libraries, AI/ML, and computational chemistry to rapidly identify novel veterinary medicines; focuses on discovering and developing small-molecule drugs for companion and farm animals addressing infectious and chronic diseases, with a proprietary pipeline of veterinary small molecules including next-generation antiparasitics and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Animol Discovery company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spotlight Innovation
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spotlight Innovation
2.2 - Growth funds investing in similar companies to Spotlight Innovation
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spotlight Innovation
4.2 - Public trading comparable groups for Spotlight Innovation
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →